About
LicensingInsightsBioLink WeeklyJob BoardNews中文Contact Us

Insights

Original research on the US-China licensing corridor, from primary sources.

2 articles published
Latest
August 14, 202615 min read

What your competitor actually got is on page 52 of their annual report

The headline on a licensing deal is a contract ceiling, not money. What actually moved — the cash at signing, the upfront after withholding tax, what the buyer's auditors decided the equity was worth, how the milestone stack splits — sits in filings anyone can read in an afternoon.

Read article

In This Article

  • Out-licensing
  • Deal terms
  • Primary filings
  • HKEX & SEC
  • Milestones
All Articles
July 20, 2026 · 17 min read

Your asset didn't sell. The problem probably isn't the asset.

Chinese biotechs are told their assets fail to sell because the target is crowded. The deal record says otherwise: what decides the outcome is whether the licensing window is still open — and whether you spent your Phase 3 on evidence that does not travel.

Read article
Stay in the loop

New research, when we publish it

We publish original analysis on cross-border licensing a few times a year. No cadence filler.